B. Riley Forecasts Cytokinetics’ Q1 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) – Analysts at B. Riley issued their Q1 2026 earnings per share estimates for shares of Cytokinetics in a report issued on Monday, November 10th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of ($1.62) per share for the quarter. B. Riley has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.62) EPS, Q3 2026 earnings at ($1.67) EPS and Q4 2026 earnings at ($1.56) EPS.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $6.05 million. The company’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same period last year, the business posted ($1.36) earnings per share.

Several other analysts have also recently issued reports on the stock. Bank of America upped their target price on shares of Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research report on Thursday, October 2nd. Royal Bank Of Canada boosted their price objective on Cytokinetics from $82.00 to $87.00 and gave the stock an “outperform” rating in a research note on Tuesday. Raymond James Financial started coverage on Cytokinetics in a research note on Wednesday, July 30th. They issued a “market perform” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a report on Tuesday, October 21st. Finally, Barclays boosted their target price on Cytokinetics from $71.00 to $82.00 and gave the company an “overweight” rating in a research report on Monday, October 6th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.86.

Cytokinetics Stock Down 0.8%

CYTK stock opened at $65.94 on Tuesday. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $66.98. The firm has a market capitalization of $8.06 billion, a P/E ratio of -12.93 and a beta of 0.58. The company has a fifty day simple moving average of $56.46 and a two-hundred day simple moving average of $42.63.

Institutional Investors Weigh In On Cytokinetics

Large investors have recently added to or reduced their stakes in the stock. State of Michigan Retirement System increased its position in shares of Cytokinetics by 1.1% during the first quarter. State of Michigan Retirement System now owns 28,200 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 300 shares during the period. Louisiana State Employees Retirement System grew its stake in Cytokinetics by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 33,100 shares of the biopharmaceutical company’s stock worth $1,330,000 after purchasing an additional 300 shares in the last quarter. Edgestream Partners L.P. purchased a new position in Cytokinetics during the 1st quarter worth $732,000. Jennison Associates LLC bought a new stake in Cytokinetics during the 1st quarter valued at $27,085,000. Finally, Teachers Retirement System of The State of Kentucky raised its position in Cytokinetics by 9.6% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 60,357 shares of the biopharmaceutical company’s stock valued at $2,426,000 after purchasing an additional 5,282 shares in the last quarter.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 6,757 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $60.00, for a total transaction of $405,420.00. Following the completion of the sale, the director directly owned 9,778 shares of the company’s stock, valued at approximately $586,680. The trade was a 40.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Wendell Wierenga sold 4,375 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $58.68, for a total transaction of $256,725.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at approximately $1,903,813.92. The trade was a 11.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 62,158 shares of company stock worth $3,502,145 in the last 90 days. 2.70% of the stock is owned by insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.